Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

Neumora Therapeutics stock is falling on Monday as investors in NMRA shares react to a clinical trial being put on hold by the FDA.

Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?

April 15, 2024

Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

April 15, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session

April 15, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

April 15, 2024

We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning!

Analyst Expectations for Neumora Therapeutics's Future

November 08, 2023

Via Benzinga

Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

April 15, 2024

Dollar Tree Reports Weak Earnings, Joins Tesla, Arcos Dorados And Other Big Stocks Moving Lower On Wednesday

12 Health Care Stocks Moving In Wednesday's Intraday Session

March 13, 2024

Via Benzinga

March 13, 2024

U.S. stocks were mixed, with the Dow Jones index surging more than 100 points on Wednesday.

Via Benzinga

Topics Stocks

Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days

March 13, 2024

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

March 13, 2024

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...

Via Benzinga

NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023

March 07, 2024

NMRA stock results show that Neumora Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 07, 2024

Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer

January 22, 2024

Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

12 Health Care Stocks Moving In Friday's Intraday Session

December 22, 2023

Via Benzinga

December 22, 2023

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

Via Benzinga

Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday

December 22, 2023

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition...

Via Benzinga

Topics Stocks

7 Stocks with Strong Insider Buying: December 2023

December 17, 2023

Here are just a few of the top stocks with strong insider buying that all investors may want to watch heading into 2024.

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

December 12, 2023

Shares of Salesforce, Inc.

Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

November 30, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

November 30, 2023

It's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning!

Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session

December 04, 2023

Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20...

Via Benzinga

Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study

November 27, 2023

NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia

Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 01, 2023

Neumora Therapeutics to Participate in Upcoming Conferences in November

October 30, 2023

PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday

October 10, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023

October 10, 2023

Via Benzinga

Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug

October 10, 2023

Shares of Neumora Therapeutics Inc (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange.

Via Benzinga

Topics Initial Public Offering

Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development

October 10, 2023

Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines